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Abstract 
Managing blood lipid levels is important for the treatment and prevention of diabetes, 
cardiovascular disease, and obesity. An easy-to-use, portable lipid blood test will accelerate more 
frequent testing by patients and at-risk populations. We used smartphone systems that are already 
familiar to many people. Because smartphone systems can be carried around everywhere, blood 
can be measured easily and frequently. We compared the results of lipid tests with those of 
existing clinical diagnostic laboratory methods. We found that smartphone-based point-of-care 
lipid blood tests are as accurate as hospital-grade laboratory tests. Our system will be useful for 
those who need to manage blood lipid levels to motivate them to track and control their behavior. 
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Introduction 
Total cholesterol (TC), high density lipoprotein (HDL), and triglyceride (TG) levels indicate 
blood lipid levels. Controlling blood lipid levels is known to be associated with the treatment and 
prevention of various diseases, including diabetes mellitus (1), cardiovascular risk (2), and 
obesity (3). It is important to diagnose quickly and easily using a point-of-care-testing (POCT) 
device to effectively control blood lipid levels compared to hospital examinations (4).  
By lowering the blood testing barriers, patients can check their blood more frequently. 
This gives you access to temporal changes in your biomarkers, making it easier to monitor and 
manage your health. One way to lower the test barriers is to use the familiar smartphone 
interface (5). We can take advantage of the sophisticated imaging technology and computing 
power available in smartphones. Therefore, the smartphone technology enables more accurate 
and comprehensive diagnostics. This will greatly improve preventive treatment for chronic 
metabolic diseases. 
The elemark™ lipid check is a smartphone-based in-vitro diagnostic device for self-
testing for rapid examination of three lipid markers. This device has a function to store / output 
the measured value. A whole blood sample that does not require centrifugation is used in the test 
to shorten the test time. This study examines the accuracy of the elemark™ lipid tests compared 
to hospital grade clinical diagnostic laboratory methods. 
 
 
Figure 1. Device components. (A) elemark™, (B) the elemark™ lipid check, (C) the elemarkTM 
lipid check cholesterol test strip, (D) connect the elemark™ lipid check to compatible mobile 
devices in the shown direction, (E) push the button up to lock the elemark™ lipid check.  
 
 
Methods 
The elemark™ lipid check device was developed in September 2016 as a self-testing cholesterol 
measuring device. TC, HDL and TG were measured using elemark™ compatible cholesterol test 
strips. The elemark™ System includes elemark™ Analyzer and SD LipidoCare™ lipid test strip 
(Figure 1). 
This experiment was approved by the Incheon St. Mary’s Hospital Institutional Review 
Board (IRB) in Incheon, South Korea, complied with the World Medical Association Declaration 
of Helsinki regarding ethical conduct of research involving human subjects. We followed the 
experimental procedures described in the normative references for the application of the 
International Organization for Standardization (ISO) (6,7). We anonymized the identity of the 
sample source. Because it is a simple blood test, the risk of the sample supplier is minimized. 
Minimal risk is defined as the degree and severity of harm or discomfort that may arise from 
studies not greater than the daily life of a healthy person or a routine physical or psychological 
examination (8). 
The test temperature was controlled at 20 ~ 26 ° C during the experiment. AU5800 
Analyzer (Beckman Coulter Inc., IN, USA) was used as a reference device. Total cholesterol 
(TC), triglyceride (TG) and high density lipoprotein (HDL) were measured and reported. Low 
density lipoprotein (LDL) can be calculated as TC minus HDL minus TG / 5. LDL was not 
reported in this evaluation study. 
 
Table 1. Sample distribution of total cholesterol (TC), triglyceride (TG), and high density 
lipoprotein (HDL) concentrations.  
TC concentration (mg/dL) N total % 
Below 200 mg/dL (Normal) 86 116 74.1 
200~239 mg/dL (Borderline High) 24 116 20.7 
Above 240 mg/dL (High) 6 116 5.2 
TG concentration (mg/dL) N total % 
Below 150 mg/dL (Normal) 71 116 61.2 
150~199   mg/dL (Borderline High) 22 116 19.0 
200~499   mg/dL (High) 22 116 19.0 
Above   500 mg/dL (Very high) 1 116 0.9 
HDL  concentration (mg/dL) N total % 
Below  40 mg/dL (Low) 22 116 19.0 
40~59  mg/dL (Normal) 60 116 51.7 
Above  60 mg/dL (High) 34 116 29.3 
 
The elemark™ cholesterol meter was stored at -30 ° C to 70 ° C, relative humidity of 90% or less 
and an altitude of less than 2000 meters. The cholesterol test strips (SD Biosensor LipidCare 
Lipid Profile Strips) were stored at room temperature between 2 °C and 32 °C and were used 
immediately after opening the individual pouches. 
The venous whole blood in the treated ethylenediaminetetraacetic acid (EDTA) tube was 
used for elemark™, and the venous serum blood in the treated EDTA tube was separated from 
the venous whole blood and used in the reference device (AU5800). We recruited 116 
participants for a blood test (809 women, 36 men, 70.8 ± 10.8 years) (Table 1). Samples were 
tested and analyzed within one day of blood collection. The comparison results were analyzed 
between elemark™ and AU5800. The correlation coefficient was used to evaluate the correlation 
between the two measurements (Figure 2). A detailed elemark™ user manual is attached as an 
attachment (supporting information). 
 
 
Figure 2. Test procedure. (A) Tap on the cholesterol icon to launch the app. (B) Press the Start 
Test button. (C) Use the camera of the mobile device to scan the barcode in the strip box. Once the 
cholesterol test strip is validated, the app automatically goes to the next step. (D) Insert the 
cholesterol measurement strip into the elemark™ lipid check as shown. (E) Blood samples are 
collected using a lancing device. Open the elemark™ lipid check cover, place the open end of the 
capillary into the sample area of the cholesterol test strip, and gently squeeze the capillary tube 
bulb to inject the blood sample. (F) Follow the on-screen instructions to close the cover. (G) Wait 
three minutes for analysis. (H) When the analysis is finished, the test results are displayed on the 
screen. (I) The user can check the latest test result graphically. (J) The user can check all test 
results. 
 
Tukey's fences were used to identify outliers based on interquartile range. The interquartile range 
is a measure of the statistical variance and is equivalent to the difference between 75th and 25th 
percentile. For example, if Q1 and Q3 are the lower and upper quartiles, respectively, you can 
define anomalies with any observation outside the range:  
 
[Q1 - k(Q3 - Q1), Q3 + k(Q3-Q1)]                                          (1) 
 
When k = 1.5, values out of the above range were regarded as outliers (9,10). 
 
 
Results 
We compared the results between the elemark™ and reference devices (Table 2). Linear 
regression analysis showed that TC, TG, and HDL had a high correlation between the two 
devices (TC: correlation coefficient (R) = 0.97, coefficient of determination (R2) = 0.94, p-value 
= 2.25X10-73; TG: R = 0.99, R2 = 0.98, p-value = 1.34X10-92; HDL: R = 0.97, R2 = 0.93, p-value 
= 1.67X10-69).  
 
Table 2. System accuracy  
 
<100mg/dL ≧100mg/dL 
Within 
±5mg/dL 
Within 
± 10mg/dL 
Within 
±15mg/dL 
Within 
±5% 
Within 
±10% 
Within 
±15% 
Within 
±20% 
TC N/A (Device range: 100~450mg/dL) 
87/116 
75.0% 
112/116 
96.6% 
115/116 
99.1% 
116/116 
100% 
TG 8/24 33.3% 
17/24 
70.8% 
23/24 
95.8% 
42/92 
45.7% 
71/92 
77.2% 
89/92 
96.7% 
92/92 
100% 
HDL 98/116 84.5% 
116/116 
100% 
116/116 
100% N/A (Device range: 25~95 mg/dL) 
 
The system accuracy results showed that 99.1% of the TC concentration values at 100mg/dL or 
above were within ±15% of the reference results, 96.7% of the TG concentration values at 
100mg/dL or above were within ±15% of the reference results, and 100% of the HDL 
concentration values less than 100mg/dL were within ±10mg/dL of the reference results (Table 
2).  
  
  
 
Figure 3. Regression and difference charts. (A) Total cholesterol (TC) regression chart, (B) 
percept difference chart with ±15% accuracy standard, (C) triglyceride (TG) regression chart, (D) 
percent difference chart with ±15% accuracy standard, (E) high density lipoprotein (HDL) 
regression chart, (F) percent difference chart with ±10% accuracy standard.  
 
 
 
Discussion 
We verified the accuracy of elemark™ by confirming the correlation between the whole blood 
lipid measurement values of three lipid markers (TC, TG, HDL) from elemark™ and the serum 
lipid values of the same three lipid markers from existing automated hospital equipment. 
elemarkTM satisfied the acceptance criteria for the CE approval; 95% of the individual blood-
testing parameter result shall fall within ±10mg/dL of the appropriate reference result at HDL 
concentration<100mg/dL and within ±15% of the reference result at TC and TG concentration 
≥100mg/dL (11).  
We used a smartphone-based easy-to-use and intuitive user interface (Figure 2) (12,13). 
Smartphone-based blood tests have several advantages in terms of computation, communication, 
and imaging. In addition, data generated from point-of-care devices can be easily shared with 
caregivers and healthcare professionals, helping to manage chronic disease in patients. Because 
the device is always connected to the network, data points cannot be lost, and the generated data 
can be automatically saved and configured for later analysis. Future machine learning-based 
analysis will allow us to predict cholesterol levels and calculate the risk of metabolic disease (14). 
 Our study has several limitations. We used venous blood for the elemark™ test. Capillary 
whole blood results are known to be different from venous whole blood results (15). Future 
studies showing actual use cases should use capillary whole blood. We should also be aware that 
the recruited participants were mainly from the elderly population (age: 70.8 ± 10.8). However, 
we believe that our current study of method comparison results is independent of age distribution. 
Rather, our results showed that elderly participants at high risk for cardiovascular disease 
produced accurate cholesterol diagnostics (16). 
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